Urbanucci, Alfonso
Barfeld, Stefan J.
Kytölä, Ville
Itkonen, Harri M.
Coleman, Ilsa M.
Vodák, Daniel
Sjöblom, Liisa
Sheng, Xia
Tolonen, Teemu
Minner, Sarah
Burdelski, Christoph
Kivinummi, Kati K.
Kohvakka, Annika
Kregel, Steven
Takhar, Mandeep
Alshalalfa, Mohammed
Davicioni, Elai
Erho, Nicholas
Lloyd, Paul
Karnes, R. Jeffrey
Ross, Ashley E.
Schaeffer, Edward M.
Vander Griend, Donald J.
Knapp, Stefan
Corey, Eva
Feng, Felix Y.
Nelson, Peter S.
Saatcioglu, Fahri
Knudsen, Karen E.
Tammela, Teuvo L.J.
Sauter, Guido
Schlomm, Thorsten
Nykter, Matti
Visakorpi, Tapio
Mills, Ian G.
Funding for this research was provided by:
Wellcome Trust
Prostate Cancer Foundation
University Hospitals
Pfizer
Ontario Ministry of Economic Development and Innovation
Merck
Janssen Pharmaceuticals
Eshelman Institute for Innovation, University of North Carolina at Chapel Hill
Kreftforeningen (102032)
Kreftforeningen (4521627)
Kreftforeningen (711072)
Norges Idrettshøgskole (P01CA163227)
Norges Idrettshøgskole (P50CA097186)
Genome Canada
Shenzhen Gas Corporation (1097737)
Novartis Pharma
Canada Foundation for Innovation
Boehringer Ingelheim
Norges Forskningsråd (230559)
Takeda Pharmaceutical Company
Innovative Medicines Initiative
This article is maintained by: Elsevier
Article Title: Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
Journal Title: Cell Reports
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.celrep.2017.05.049
Content Type: article
Copyright: © 2017 The Author(s).